The Development of Diabetes after Subtotal Gastrectomy with Billroth II Anastomosis for Peptic Ulcer Disease

Chien-Hua Chen¹,²,³‡, Che-Ming Hsu¹‡, Cheng-Li Lin⁴,⁵, An-Kuo Chou⁶,⁷*, Long-Bin Jeng⁸,⁹*♣

¹ Digestive Disease Center, Show-Chwan Memorial Hospital, Changhua, Taiwan, ² Hungkuang University, Taichung, Taiwan, ³ Chung Chou University of Science and Technology, Yilan Township, Changhua County, Taiwan, ⁴ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, ⁵ College of Medicine, China Medical University, Taichung, Taiwan, ⁶ Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan, ⁷ School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, ⁸ Graduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, ⁹ Department of Surgery, Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan

* These authors contributed equally to this work.
‡ Co-first author.
* otc.Jeng@gmail.com

Abstract

Purpose
A duodenal bypass after a Roux-en-Y gastric bypass operation for obesity can ameliorate the development of diabetes mellitus (DM). We attempted to determine the subsequent risk of developing DM after subtotal gastrectomy with Billroth II anastomosis (SGBIIA) for peptic ulcer disease (PUD).

Methods
We identified 662 patients undergoing SGBIIA for PUD between 2000 and 2011 from the Longitudinal Health Insurance Database as the study cohort, and we randomly selected 2647 controls from the peptic ulcer population not undergoing SGBIIA and were frequency-matched by age, sex, and index year for the control cohort. All patient cases in both cohorts were followed until the end of 2011 to measure the incidence of DM. We analyzed DM risk by using a Cox proportional hazards regression model.

Results
The patients who underwent SGBIIA demonstrated a lower cumulative incidence of DM compared with the control cohort (log-rank test, \( P < .001 \) and 6.73 vs 12.6 per 1000 person-y). The difference in the DM risk between patients with and without SGBIIA increased gradually with the follow-up duration. Age and sex did not affect the subsequent risk of developing DM, according to the multivariable Cox regression model. Nevertheless, the SGBIIA cohort exhibited a lower DM risk after we adjusted for the comorbidities of hypertension, hyperlipidemia, and coronary artery disease (adjusted hazard ratio (aHR): 0.56, 95% confidence...
Introduction

With the introduction of histamine-2 antagonists and proton pump inhibitors (PPIs) as well as the eradication of Helicobacter pylori (HP), the rate of elective operations for peptic ulcer disease (PUD) has been declining for the past 30 years [1]. However, surgery is still recommended for uncontrolled hemorrhage, gastrointestinal tract obstruction, or malignancy concerns [2]. A definite operation for PUD was considered unnecessary because of the introduction of PPIs and HP eradication after an improved understating of PUD pathogenesis [3]. Nevertheless, the location and extension of the ulcers responsible are the most critical determinants of the surgical method to be applied such as the decision to perform a gastrectomy for PUD. Resecting gastric ulcers located in a lesser curvature of the stomach is challenging because of the technical complexities induced by the rich blood arcades in the left gastric artery and obstruction tendencies caused by deformities of the gastric remnants after a wedge gastrectomy [4]. Regarding duodenal ulcers spanning more than 2 cm, the risk of leakage increases with a simple omental patch repair [5]. Therefore, a subtotal gastrectomy with Billroth II anastomosis (SGBIIA) is still recommended in targeting these PUDs.

The prevalence of diabetes mellitus (DM) is increasing rapidly worldwide, and type 2 DM constitutes more than 95% of DM-classified subgroups [6]. In 2010, the reported prevalence rates of DM in the adult populations of the United Kingdom, the United States, and mainland China were approximately 7%, 11%, and 15%, respectively [7–9]. The pathogenesis of type 2 DM includes insulin resistance and an insulin secretory response that is inadequate in fulfilling biological requirements. DM has imposed a substantial burden on socioeconomic status and public health because it is associated with the long-term damage of various organs such as the eyes, kidneys, the brain, and cardiovascular organs [10]. For example, the 5 most frequent complications of DM are amputation of the lower extremities, acute myocardial infarction, stroke, end-stage renal disease, and hyperglycemic-crisis-induced mortality [11].

A study reported that 85% of type 2 DM cases can result in remission after a Roux-en-Y bypass operation [12]. Duodenal diversion from contact with ingested nutrients, rather than weight loss, is reportedly a potential mechanism involved in the remission of type 2 DM [13]. Furthermore, SGBIIA is also a type of operation with a duodenal bypass because a gastrojejunostomy is performed after a gastrectomy.

In this study, we hypothesized that a history of SGBIIA for PUD treatment might be associated with a reduced risk of DM development. We conducted a nationwide population-based cohort study by analyzing data from a nationwide medical database, the National Health...
Insurance Research Database (NHIRD), to assess the association between SGBIIA and subsequent DM development.

Methods

Data Source

We used reimbursement claims data from the Longitudinal Health Insurance Database 2000 (LHID2000), established by the National Health Research Institutes (NHRI) under the Department of Health. LHID2000 contains all inpatient and outpatient medical claims for approximately 1 million people who were randomly sampled from the registry for beneficiaries of the NHIRD in the year 2000. The NHIRD is a nationwide database containing the claims records from Taiwan’s mandatory National Health Insurance (NHI) program, which was launched in 1995 and covers more than 99% of the population of Taiwan (23.74 million people) [14]. The NHRI have encrypted all patient identification numbers for privacy protection. The NHIRD comprises numerous registration data, and the details have been published in previous studies [15, 16]. Diagnoses were coded based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). We obtained the data files (LHID2000) from the NHRI, which is a non-profit organization and the largest health research institute in Taiwan with many good statisticians and computer experts. The NHRI is responsible to provide appropriate data files to users. The distributions of sex, age and health care cost between the one million file (LHID2000) and the 23 million population were similar. The NHRI assigned a random number for each person by the method designed by Knuth, Park and Miller [17, 18].

Data Availability Statement

All data and related metadata were deposited in an appropriate public repository in the National Health Research Institutes (NHRI). The data on the study population that were obtained from the NHIRD (http://nhird.nhri.org.tw/en/index.html) are maintained in the NHIRD (http://nhird.nhri.org.tw/). The NHRI is a nonprofit foundation established by the government. Only citizens of the Republic of China who fulfill the requirements of conducting research projects are eligible to apply for the NHIRD. The use of NHIRD is limited to research purposes only. Applicants must follow the Computer-Processed Personal Data Protection Law (http://www.winklerpartners.com/?p=987) and related regulations of National Health Insurance Administration and NHRI, and an agreement must be signed by the applicant and his/her supervisor upon application submission. All applications are reviewed for approval of data release.

Ethics Statement

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH-104-REC2-115). The IRB also specifically waived the consent requirement.

Sampled Participants

Fig 1 shows the participant selection process for the 2 study cohorts. All patients with a history of PUD (ICD-9-CM 531–533) between 1998 and 2010 were included in the study population. Patients who underwent SGBIIA (ICD-9-CM procedural code 43.7) were assigned to the
297,054 peptic ulcer disease patients (ICD-9-CM 531-533) from the one million insured individuals who were newly diagnosed

Patients with subtotal gastrectomy with Billroth II anastomosis in 1998-2011. (n=852)

Excluded patients with diabetes mellitus before index date (n=142), or under 20 years of age and missing information about age or sex (n=48)

Subtotal gastrectomy with Billroth II anastomosis cases without diabetes mellitus at baseline. (n=662)

Patients without subtotal gastrectomy with Billroth II anastomosis in 1998-2011 (n=296,202)

Using the same exclusion criteria as the study cohort and 1:4 randomly frequency matched with age-, sex-, and index year

Finally, 2,647 peptic ulcer disease controls without diabetes mellitus at baseline.

Total 3,309 study subjects were follow-up until diagnosis of type 2 diabetes mellitus, the time of subject was censored, or up to the end of 2011.

Fig 1. Participant selection process.

doi:10.1371/journal.pone.0167321.g001

SGBIIA cohort. Patients with a history of DM (ICD-9-CM 250), those younger than 20 years, and those with incomplete information were excluded. The date of SGBIIA was circumscribed as the index date. The non-SGBIIA cohort was established by randomly selecting the remaining patients who had PUD, but did not undergo SGBIIA. For each patient in the SGBIIA cohort, 4 non-SGBIIA patients without a history of diabetes were identified and frequency-matched by age (within a span of 5 y), sex, and the year of the index date. Baseline comorbidities included hypertension (ICD-9-CM 401–405), hyperlipidemia (ICD-9-CM 272), coronary artery disease (ICD-9-CM 410–414), stroke (ICD-9-CM 430–438), and chronic obstructive pulmonary disease (COPD) (ICD-9-CM 490, 491, and 496).

Outcome

The main outcome was based on the claims records with a diagnosis of type 2 DM (ICD-9-CM codes 250.x0 and 250.x2) during follow-up. The patient cases were followed from the index date to the date of type 2 DM diagnosis, the date of withdrawal from the insurance program, censorship because of death, or the end date of the database (ie, December 31, 2011).

Statistical Analysis

We compared and examined the distributions of sex, age, and baseline comorbidities between the cohorts by using the Chi-square test to examine categorical variables and Student’s t test to analyze continuous variables. We assessed the cumulative incidences of type 2 DM between the SGBIIA and non-SGBIIA cohorts by using the Kaplan–Meier method, and we evaluated the differences by performing a log-rank test. The follow-up period (in person-years) was used to estimate the incidence density rates of type 2 DM. The incidence rate ratio (IRR) of the
SGBIIA cohort to the non-SGBIIA cohort and the 95% confidence interval (CI) were estimated using a Poisson regression model. We also employed univariable and multivariable Cox proportional hazards regression models to assess the hazard ratio (HR) and 95% CI for type 2 DM. Variables in the multivariable model included sex, age, hypertension, hyperlipidemia, and coronary artery disease; all the confounding factors demonstrated a significant difference in the univariable Cox model. All analyses were performed using SAS software (version 9.4, SAS Institute Inc., North Carolina, USA); \( P < .05 \) indicated statistical significance.

**Results**

Fig 2 illustrates the cumulative type 2 DM incidence curves for the 2 cohorts, indicating that the incidence of DM in the SGBIIA cohort is significantly lower than that in the non-SGBIIA cohort (log-rank test, \( P < .001 \)) during the mean follow-up period of 3.59 ± 3.61 (0.003–13.3) years for the SGBIIA cohort and 5.32 ± 3.71 (0.005–13.9) years for the non-SGBIIA cohort.

Table 1 lists the comparisons of the demographic characteristics and comorbidities between the PUD patients who underwent subtotal SGBIIA and those who did not. The SGBIIA cohort comprised 662 persons, whereas the non-SGBIIA cohort was composed of 2647 counterparts. In this study, 68.7% of the patients were men, and 54.7% of the patients were older than 65 years. The mean ages in the SGBIIA and non-SGBIIA cohorts were 65.0 years (SD = 14.5) and 64.7 years (SD = 14.5), respectively. Patients who did not undergo SGBIIA had a higher
prevalence of comorbidities of hypertension, hyperlipidemia, coronary artery disease, and COPD (P < .05).

Table 2 shows the results of the univariable and multivariable Cox proportional hazards regression models used for our analysis of the risk of variables contributing to type 2 DM. The risk of developing type 2 DM was greater for patients with the comorbidities of hypertension (adjusted HR (aHR) = 1.34, 95% CI = 1.09–1.64) and hyperlipidemia (aHR = 1.50, 95% CI = 1.22–1.85).

Table 1. Comparisons of demographic characteristics and comorbidities between PUD patients with and without SGBIIA

| Subtotal gastrectomy with Billroth II anastomosis | No (N = 2647) | Yes (N = 662) | p-value |
|-----------------------------------------------|--------------|--------------|---------|
| Gender                                        |              |              |         |
| Women                                         | 828(31.3)    | 207(31.3)    | 0.99    |
| Men                                           | 1819(68.7)   | 455(68.7)    |         |
| Age stratified                                |              |              |         |
| ≤ 49                                          | 440(16.6)    | 110(16.6)    | 0.99    |
| 50–64                                         | 760(28.7)    | 190(28.7)    |         |
| 65+                                           | 1447(54.7)   | 362(54.7)    |         |
| Age, mean±SD                                 | 64.7(14.5)   | 65.0(14.5)   | 0.61    |
| Comorbidity                                   |              |              |         |
| Hypertension                                  | 1383(52.3)   | 309(46.7)    | 0.01    |
| Hyperlipidemia                                | 650(24.6)    | 127(19.2)    | 0.004   |
| Coronary artery disease                       | 780(29.5)    | 158(23.9)    | 0.004   |
| Stroke                                        | 207(7.82)    | 59(8.91)     | 0.36    |
| COPD                                          | 637(24.1)    | 128(19.3)    | 0.01    |

Chi-square test

a T test
Mean case group follow-up time = 3.59 (SD = 3.61)
Mean control group follow-up time = 5.32 (SD = 3.71)

doi:10.1371/journal.pone.0167321.t001

Table 2. HRs of type 2 DM in association with age, sex, and comorbidities in univariable and multivariable Cox regression models

| Variable                                | Crude\(^\text{a}\) | Adjusted\(^\text{b}\) |
|-----------------------------------------|--------------------|----------------------|
|                                         | HR (95%CI)         | HR (95%CI)           |
| Subtotal gastrectomy with Billroth II anastomosis | 0.53 (0.38,0.74)** | 0.56 (0.40,0.78)** |
| Age, years                              | 1.00 (1.00, 1.01)  | -                    |
| Sex (female vs male)                    | 0.90 (0.74, 1.09)  | -                    |
| Baseline co-morbidities (yes vs no)     |                    |                      |
| Hypertension                            | 1.50 (1.25,1.80)** | 1.34 (1.09,1.64)**  |
| Hyperlipidemia                          | 1.66 (1.37,2.03)** | 1.50 (1.22,1.85)**  |
| Coronary artery disease                 | 1.27 (1.04, 1.55)* | 1.00 (0.81,1.24)    |
| Stroke                                  | 0.81 (0.52, 1.25)  | -                    |
| COPD                                    | 1.01 (0.80, 1.27)  | -                    |

Crude HR\(^\text{a}\) represents the relative hazard ratio; Adjusted HR\(^\text{b}\) represents adjusted hazard ratio: mutually adjusted for comorbidities of hypertension, hyperlipidemia, and coronary artery disease in the Cox proportional hazard regression models.

\*P < .05
\***P < .001

doi:10.1371/journal.pone.0167321.t002
Table 3 lists a comparison of the incidence densities of the type 2 DM HRs between PUD patients who underwent SGBIIA versus those who did not after they were stratified by demographic characteristics and comorbidities. During the 12-year follow-up, we noted a lower incidence density rate of type 2 DM in the SGBIIA cohort compared with the non-SGBIIA cohort (6.73 and 12.6, respectively, per 1000 person-y), with an IRR of 0.53 (95% CI = 0.38–0.74). The IRR of type 2 DM in the SGBIIA cohort was lower than that in the non-SGBIIA cohort for both sexes. Compared with the non-SGBIIA cohort, the SGBIIA cohort was associated with a lower risk of type 2 DM, irrespective of the age group. A greater incidence density rate of type 2 DM was found in patients with comorbidity in both groups. However, the patients who underwent SGBIIA were at a substantially lower risk of type 2 DM compared with those who did not when they had a comorbidity (IRR = 0.50, 95% CI = 0.31–0.78). Notably, the risk of developing type 2 DM did not increase with increasing age in Table 2. Moreover, Table 3 shows that the rate of developing type 2 DM peaked in individuals with age 50–64 years rather than in the elderly (greater than 65 years).

Discussion

Table 4 shows that the incidence of PUD decreased progressively in our study population, which might be explained by improving living conditions with lower HP infection and the introduction of PPIs. The incidence in our study was similar to those of several former reports in Taiwan with incidence of 9.52% per 1000 person-years in a 2001–2009 cohort study based on LHID 2000 and prevalence of 9.4% in a cross-sectional study of individuals for self-paid physical check-up conducted in 2008 [19, 20]. In 1 million people, 297,054 patients received a diagnosis of PUD; therefore, the prevalence was approximately 29.7% in our study. Moreover, 0.29% (852 of 297,054) of the patients with PUD would undergo SGBIIA in our study. In accordance with the literature, our findings revealed that SGBIIA, which might be indicative of the
presence of complicated PUD, was performed mostly in male patients and those older than 65 years. The most common reasons for the propensity of older adults to incur complicated PUD may include a greater prevalence in the HP infection rate and the associated poor mucosal resistance for older patients, a linear increase in non-steroidal anti-inflammatory drug (NSAID) usage with age, and a greater prevalence of smoking habits in the older population [21–24]. With the exception of an HP infection, unrelated to the risk of perforation, all the mentioned risk factors are associated with the risks of hemorrhage and perforation in patients with PUD. Moreover, the prevalence rate of HP infection, NSAID usage, and smoking habits is higher in men.

Our study findings implied that hypertension and hyperlipidemia were associated with an increased risk of DM development. In murine and human β cells, a study revealed that low-density lipoproteins could lower both the proliferation of β cells and maximal insulin secretion after glucose stimulation [25]. By contrast, another study reported that high-density lipoproteins could prevent basal and interleukin-1 or glucose-stimulated β-cell apoptosis. Moreover, the elevated levels of free fatty acids are a critical determinant of insulin resistance [26]. Hypertension and DM are a negative combination [27]. Hypertension can activate the renin-angiotensin-aldosterone system (RAAS), and they influence each other. Through RAAS activation, inflammation and oxidative stress are induced to increase insulin resistance [28]. Moreover, insulin resistance can result in vascular smooth muscle proliferation and arterial stiffness, increase vascular tone, and reduce vasodilation, leading to hypertension [29].

The inverse association between SGBIIA and DM is attributable to a greater prevalence of critical DM risk factors in patients who did not undergo SGBIIA compared with those who did. Moreover, the mean-follow-up period was shorter in patients who underwent SGBIIA than that in those without undergoing SGBIIA. However, one can reasonably conclude that the reduced risk of DM observed in the SGBIIA patients was more likely a consequential effect of the SGBIIA status because the possible confounding effect of DM risk factors was minimized substantially in our study (Table 2). We observed a consistent drop in the DM risk post-SGBIIA in both sexes and for all age groups. Furthermore, the inverse association between SGBIIA and DM was greater in the presence of a comorbidity because the IRR of DM was significantly lower in the SGBIIA patients with a comorbidity compared with those without

| year | Total population | PUD | IR |
|------|-----------------|-----|----|
| 1998 | 638080          | 10240 | 16.05 |
| 1999 | 653852          | 23627 | 36.14 |
| 2000 | 668657          | 23150 | 34.62 |
| 2001 | 673461          | 18032 | 26.78 |
| 2002 | 677752          | 15553 | 22.95 |
| 2003 | 683220          | 12519 | 18.32 |
| 2004 | 688815          | 11838 | 17.19 |
| 2005 | 697144          | 9533  | 13.67 |
| 2006 | 703958          | 8295  | 11.78 |
| 2007 | 710048          | 7672  | 10.8 |
| 2008 | 716391          | 6781  | 9.47 |
| 2009 | 721504          | 6376  | 8.84 |
| 2010 | 727666          | 5690  | 7.82 |
| 2011 | 732446          | 4264  | 5.82 |

IR: Incidence rate per 1,000

doi:10.1371/journal.pone.0167321.t004
In addition, our findings also consistently revealed that the inverse association increased progressively over the whole 12-year-long follow-up duration despite that the mean-follow-up period was shorter in patients who underwent SGBIIA than that in those without undergoing SGBIIA (Fig 2). These findings, combined with the results of the subgroup analyses confirm the possible inverse association between SGBIIA and DM. However, it requires more studies to clarify whether it is epiphenomenon or causal relationship.

Several studies have suggested that the inverse association between SGBIIA and DM may be due to the following 4 mechanisms. First, starvation or a reduced fat mass after a gastrectomy leads to lower lipid oxidation and enhanced insulin sensitivity [30]. Moreover, insulin secretion can be enhanced after weight loss [31]. Second, ghrelin can increase the hypothalamic expression of neuropeptide Y to stimulate appetite and lessen insulin secretion. However, the level of ghrelin, which is secreted chiefly by oxyntic cells in the stomach, decreases after a gastrectomy [32]. Third, the proximal intestines contribute to the regulation of the glucose metabolism, as suggested by foregut theory [33]. The direct passage of nutrients to the intestinal foregut with a stomach bypass triggers the counter-regulation of anti-secretin, which delays the insulin response and impairs insulin action. Finally, the distal intestines can regulate the secretion of the gut hormone, as suggested by hindgut theory, to maintain the glucose metabolism in a state of homeostasis [34, 35]. The rapid transit of undigested nutrients to the distal intestines upregulates the production of glucagon-like peptide 1 (GLP-1) and peptide-YY; moreover, GLP-1 can stimulate insulin secretion and antagonizes β-cell apoptosis, whereas peptide-YY can reduce insulin resistance. Therefore, the mentioned mechanisms interact with each other, and others cannot necessarily be precluded [36].

To the best of our knowledge, this is the first population-based study to investigate whether SGBIIA for PUD might be inversely associated with a reduced risk of DM development. We adopted a longitudinal design, rather than a cross-sectional approach, to evaluate this association. The statistical analysis results were strengthened through our use of the national database, which contained the relevant medical data of a representative cohort of 1 million people over a 12-year observation period. Furthermore, the sampled patients were from a stable population of Taiwan participating in the NHI program, which includes the records of approximately 99% of the population.

Our study had several limitations. First, we may have overlooked potential confounding factors because the NHIRD does not provide detailed information regarding the DM-related lifestyle, socioeconomic status, and the family history of patients. However, we controlled for potential DM-associated comorbidities in our study, and SGBIIA was found to be inversely associated with the development of DM. Second, patients who were not covered by the NHI program could not be included in our study population. Nevertheless, this program currently covers more than 99% of the population of Taiwan. Finally, it is difficult to clearly depict the precise mechanism for the protective effect of SGBIIA against DM. However, the mentioned 4 possible mechanisms always interact with each other and cannot operate independently. Furthermore, an inverse association between SGBIIA and ischemic stroke, rather than hemorrhagic stroke, was also consistently demonstrated in our former publication [37].

In conclusion, this population-based cohort study revealed that SGBIIA was associated with a reduced risk of DM development, and the inverse association was greater in the presence of a comorbidity.

Acknowledgments

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019), China Medical University
Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

**Author Contributions**

**Conceptualization:** CHC LBJ.

**Data curation:** CHC CMH CLL AKC LBJ.

**Formal analysis:** CHC CMH CLL AKC LBJ.

**Funding acquisition:** LBJ.

**Investigation:** CHC LBJ.

**Methodology:** CLL LBJ.

**Project administration:** LBJ.

**Resources:** CHC LBJ.

**Software:** CLL LBJ.

**Supervision:** LBJ.

**Validation:** CHC CMH CLL AKC LBJ.

**Visualization:** CHC CMH CLL AKC LBJ.

**Writing – original draft:** CHC CMH CLL AKC LBJ.

**Writing – review & editing:** CHC CMH CLL AKC LBJ.

**References**

1. Lee CW, Sarosi GA. Emergency ulcer surgery. Surg Clin North Am. 2011; 91: 1001–1013. doi: 10.1016/j.suc.2011.06.008 PMID: 21889026

2. Schwesinger WH, Page CP, Sirinek KR, Gaskill HV III, Melnick G, Strodel WE. Operations for peptic ulcer disease: paradigm lost. J Gastrointest Surg. 2002; 5: 438–443.

3. Ng EK, Lam YH, Sung JJ, Yung MY, To KF, Chan AC, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000; 231: 153–158. PMID: 10674604

4. McGee GS, Sawyers JL. Perforated gastric ulcer. A plea for management by primary gastric resection. Arch Surg 1987; 122: 555–561. PMID: 3579566

5. Gupta S, Kaushik R, Sharma R, Attri A. The management of large perforations of duodenal ulcers. BMC Surg 2005; 5: 15. doi: 10.1186/1471-2482-5-15 PMID: 15978134

6. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011; 343: d7163. doi: 10.1136/bmj.d7163 PMID: 22123912

7. Holman N, Forouhi NG, Goyder E, Wild SH. The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010–2030. Diabetic Med 2011; 28: 575–582. doi: 10.1111/j.1464-5491.2010.03216.x PMID: 21480968

8. National Diabetes Clearinghouse. National Diabetes Statistics 2011. National Institute of Health, USA. http://diabetes.niddk.nih.gov/dm/pubs/statistics/IDiagnosed20.

9. Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 2425–2426.
10. Mellitus Diabetes. Diagnosis and classification of diabetes mellitus. Diabetes care 2005; 28: S37. PMID: 15618111

11. Gregg EW, Li Y, Wang J, Burrows NR, Ali MA, Rolka D, et al. Changes in diabetes-related complications in the United States, 1980–2010. N Engl J Med 2014; 370: 1514–1523. doi: 10.1056/NEJMa1310799 PMID: 24738668

12. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annual Rev Med 2010; 61: 393–411.

13. Cohen RV, Rubino F, Schiavon C, Cummings DE. Diabetes remission without weight loss following duodenal bypass surgery. Surg Obes Relat Dis 2012; 8: e66–e68. doi: 10.1016/j.soard.2011.07.007 PMID: 21925965

14. Cheng TM. Taiwan’s National Health Insurance system: high value for the dollar. In Okma K.G.H. and Crivelli L. ed. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific, 2009, pp. 71–204.

15. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JT, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 2014; 13: 1774–1780.

16. Chen YK, Yeh JH, Lin CL, Peng CL, Sung FC, Hwang IM, et al. Cancer risk in patients with cholelithiasis and after cholecystectomy: a nationwide cohort study. J Gastroenterol 2014; 49: 923–931. doi: 10.1007/s00535-013-0846-6 PMID: 23807230

17. Knuth DE. The Art of Computer Programming, Volume 2: Seminumerical Algorithms 1981.

18. Jaypee BM. Random number generators: good ones are hard to find. Communications of the ACM 1988; 31: 1192–1201.

19. Liao CH, Chang CS, Chang SN, Muo CH, Lane HY, Sung FC, et al. The association of peptic ulcer and schizophrenia: a population-based study. Journal of Psychosomatic Research 2014; 77: 541–546. doi: 10.1016/j.jpsychres.2014.08.005 PMID: 25199406

20. Wang FW, Tu MS, Mar GY, Chuang HY, Yu HC, Cheng LC, et al. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World Journal of Gastroenterology 2011; 17: 1199–1203. doi: 10.3748/wjg.v17.i9.1199 PMID: 21448426

21. Lockrey G, Lim L. Peptic ulcer disease in older people. Journal of Clinical Practice and Research 2011; 41: 58–61.

22. Wysocki A, Budzynski P, Kulawiak J, Drozdz W. Changes in the localization of perforated peptic ulcer and its relation to gender and age of the patients throughout the last 45 years. World J Surg 2011; 35: 811–816. doi: 10.1007/s00268-010-0917-2 PMID: 21267567

23. Thorsen K, Soreide JA, Kvaloy JT, Glomsaker T, Soreide K. Epidemiology of perforated peptic ulcer: Age- and gender- adjusted analysis of incidence and mortality. World J Gastroenterol 2013; 19: 347–354. doi: 10.3748/wjg.v19.i9.347 PMID: 23372356

24. Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet 2009; 374: 1449–1461. doi: 10.1016/S0140-6736(09)60227-2 PMID: 19683340

25. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic β-cells. Endocrinology 2009; 150: 4521–4530. doi: 10.1210/en.2009-0252 PMID: 19628574

26. Chu X, Liu L, Na L, Lu H, Li S, Li Y, et al. Sterol regulatory element-binding protein-1c mediates increase of postprandial stearic acid, a potential target for improving insulin resistance, in hyperlipidemia. Diabetes 2013; 62: 561–571. doi: 10.2337/db12-0139 PMID: 22966071

27. Ferrannini E, Chusman WC. Diabetes and hypertension: the bad company. The Lancet 2012; 380: 601–610.

28. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway. Curr Atheroscler Rep 2012; 14: 160–166. doi: 10.1007/s11883-012-0227-2 PMID: 22281657

29. Mugo MN, Stump CS, Rao PG, Sowers JR. Chapter 34: Hypertension and Diabetes Mellitus. Hypertension: A Companion to Braunwald's Heart Disease. Copyright Elsevier, 2007.

30. Fransilis-Kallunki A, Rissanen A, Ekstrand A, Ollus A, Groop L. Weight loss by very-low-calorie diets: effects on substrate oxidation, energy expenditure, and insulin sensitivity in obese subjects. Am J Clin Nutr 1992; 56 (Suppl 1): 247S–248S.

31. Cummings S, Apovian CM, Khodaifar L. Obesity surgery: evidence for diabetes prevention/management. J Am Diet Assoc 2008; 108 (4 Suppl 1): S40–S44.

32. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass...
and sleeve gastrectomy: A prospective, double blind study. Ann Surg 2008; 247: 401–407. doi: 10.1097/SLA.0b013e318156f012 PMID: 18376181

33. Rubino F, Forione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741–749. doi: 10.1097/01.sla.0000224726.61448.1b PMID: 17060767

34. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145–5148. doi: 10.1210/en.2003-1147 PMID: 14645210

35. Gill RS, Birch DW, Shi X, Sharma AM, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: a systemic review. Surgery for Obesity and related Diseases 2010; 6: 707–713.

36. Lee WJ, Chang KC, Ser KH, Lee YC, Chen SC, Chen JC, et al. Gastric bypass vs gastrectomy for type 2 diabetes mellitus. Arch Surg 2011; 146: 143–148. doi: 10.1001/archsurg.2010.326 PMID: 21339423

37. Chen CH, Lin CL, Kao CH. Subtotal Gastrectomy With Billroth II Anastomosis Is Associated With a Low Risk of Ischemic Stroke in Peptic Ulcer Disease Patients: A Nationwide Population-Based Study. Medicine 2016; 95: e3481. doi: 10.1097/MD.0000000000003481 PMID: 27100454